Acumen Pharmaceuticals, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.39 | $-0.45 | -15.4% | Miss |
| Q12026 FY2026 | $-0.40 | $-0.33 | +18.1% | Beat |
| Q42025 FY2025 | $-0.50 | $-0.41 | +18.0% | Beat |
Back to ABOS overview · ABOS holders · ABOS KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.